**Tissue Bank, Ancillary/Correlative, or Xenograft Trials with Additional Risk Oversight at Multiple Institutions**

The principal investigator will be responsible for the conduct of this study at all participating institutions, including the tissue sample and/or specimen collection, handling and use, overseeing participant safety, executing the data and safety monitoring (DSM) plan, and complying with all reporting requirements to local and federal authorities. This oversight will be accomplished through additional oversight from the Data and Safety Monitoring Committee (DSMC) at the University of Colorado Cancer Center (CU Cancer Center). The DSMC is responsible for ensuring data quality and study participant safety for all studies at the CU Cancer Center. A summary of the DSMC’s activities is as follows:

• Conduct of internal audits

• Ongoing review of all serious adverse events (SAEs) and unanticipated problems (UAPs)

• Has the authority to suspend studies for safety or conduct issues

• May submit recommendations for corrective actions to the CU Cancer Center’s Executive Committee

Per the CU Cancer Center Institutional DSM Plan, SAEs and UAPs are reported to the DSMC, IRB and the principal investigator per protocol. All SAEs and UAPs are to be reported to the DSMC within 7 (for fatal or life-threatening events) or 15 (non-life-threatening events) calendar days of the investigator receiving notification of the occurrence.

Study audits by the DSMC will consist of a review of the regulatory documents, consent forms, and source data verification. Documentation of the audit will then need to be submitted by the PI to the IRB of record at the time of the continuing review.